Third Harmonic Bios chief medical officer sells 40,095 in stock
THRD Stock | USD 10.79 0.17 1.55% |
About 62% of Third Harmonic's investor base is looking to short. The analysis of the overall investor sentiment regarding Third Harmonic Bio suggests that many traders are alarmed. The current market sentiment, together with Third Harmonic's historical and current headlines, can help investors time the market. In addition, many technical investors use Third Harmonic Bio stock news signals to limit their universe of possible portfolio assets.
Third |
Third Harmonic Bios chief medical officer sells 40,095 in stock
Read at investing.com
Third Harmonic Fundamental Analysis
We analyze Third Harmonic's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Third Harmonic using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Third Harmonic based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Asset
Return On Asset Comparative Analysis
Third Harmonic is currently under evaluation in return on asset category among its peers. Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Third Harmonic Bio Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Third Harmonic stock to make a market-neutral strategy. Peer analysis of Third Harmonic could also be used in its relative valuation, which is a method of valuing Third Harmonic by comparing valuation metrics with similar companies.
Peers
Third Harmonic Related Equities
SNSE | Sensei Biotherapeutics | 1.92 | ||||
RVMD | Revolution Medicines | 0.20 | ||||
EWTX | Edgewise Therapeutics | 0.08 | ||||
PMVP | Pmv Pharmaceuticals | 1.95 | ||||
ACRV | Acrivon Therapeutics, | 3.17 | ||||
CGEM | Cullinan Oncology | 3.72 | ||||
NXTC | NextCure | 4.49 | ||||
RLYB | Rallybio Corp | 4.76 | ||||
PASG | Passage Bio | 5.71 | ||||
HOWL | Werewolf Therapeutics | 7.10 | ||||
NUVB | Nuvation Bio | 7.38 | ||||
GLUE | Monte Rosa | 8.27 |
Complementary Tools for Third Stock analysis
When running Third Harmonic's price analysis, check to measure Third Harmonic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Third Harmonic is operating at the current time. Most of Third Harmonic's value examination focuses on studying past and present price action to predict the probability of Third Harmonic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Third Harmonic's price. Additionally, you may evaluate how the addition of Third Harmonic to your portfolios can decrease your overall portfolio volatility.
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Money Managers Screen money managers from public funds and ETFs managed around the world |